UCB Pharma GmbH
Pharmaceutical Companies · Mettmann
UCB Pharma GmbH is the German subsidiary of belgischen Pharmaunternehmens UCB S, based in Mettmann.
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
UCB Pharma GmbH Address & Contact
Company profile
1928
Founded
9.400+
Employees
UCB Pharma GmbH Overview
UCB Pharma GmbH is the German subsidiary of UCB SA, a Belgian biopharmaceutical company headquartered in Brussels. Founded in 1928 under the name Union Chimique Belge (Belgian Chemical Union), UCB has fully focused on the fields of neurology and immunology over the years. The company employs around 9,400 people worldwide and is listed on Euronext Brussels. The German branch in Mettmann, North Rhine-Westphalia, plays an important role in the German market, overseeing both sales channels and marketing strategies for UCB’s products in Germany.
Field of Activity & Products
UCB focuses on two therapeutic areas: neurology and immunology. In neurology, the company offers important treatment options for diseases such as epilepsy, Parkinson's, and myasthenia gravis. Keppra (levetiracetam) is one of the most prescribed antiepileptic drugs worldwide and is a central component of the portfolio. This is complemented by Vimpat (lacosamide) and Briviact (brivaracetam), which are also used to treat epilepsy. In neurological therapy, UCB also emphasizes innovations for the treatment of rare diseases. One example is Zilbrysq (zilucoplan), which was developed for the treatment of myasthenia gravis.
In the field of immunology, UCB focuses on autoimmune diseases and offers highly effective therapies such as Cimzia (certolizumab pegol), a PEGylated anti-TNF biologic. Bimzelx (bimekizumab) is another significant advancement that acts as an IL-17A/F inhibitor specifically for the treatment of psoriasis. These products have given UCB a significant position in the field of immunotherapies.
Research & Regulation
UCB invests significantly in research and development, approximately 25 percent of its revenue, which is remarkable for a company of its size. This research activity is not only limited to the development of new drugs but also includes improving existing therapies and exploring patient-specific treatment approaches. UCB pursues a strong patient orientation and develops targeted research strategies to sustainably improve the quality of life for affected individuals.
The products from UCB are subject to strict regulations by the Federal Institute for Drugs and Medical Devices (BfArM) as well as the European Medicines Agency (EMA). UCB is also an active member of the Association of Research-Based Pharmaceutical Companies (vfa), which gives the company influence over political and social issues in healthcare.
Regional Importance
The importance of UCB Pharma GmbH in Mettmann goes beyond mere economic contribution. The company supports regional initiatives for health promotion and cooperates with local medical facilities and universities. Through these partnerships, UCB promotes research and education in the health sector, contributing to the strengthening of the workforce and medical care in the region.
Another aspect of the regional significance of UCB is its contribution to job creation in North Rhine-Westphalia, where the company not only employs highly qualified personnel but also offers attractive training positions. These investments in education and workforce development not only secure UCB's future competitiveness but also contribute to the economic stability of the region.
Unique Features and Innovativeness
UCB sets itself apart from other companies through its strong innovation profile. In addition to the aforementioned products, UCB is distinguished by its ongoing research projects and clinical trials focusing on the discovery of new molecules and therapies. One example is the commitment to the development of therapies that address the needs of patients with severe and chronic conditions.
Collaborations with academic institutions and research facilities are an essential part of UCB's innovation strategy. These partnerships enable the company to incorporate the latest scientific findings into product development and align developments with the actual needs of patients.
More information: Pharmaceutical companies in North Rhine-Westphalia or all pharmaceutical companies in Germany on Sanoliste.
```Frequently asked questions about UCB Pharma GmbH
What does UCB Pharma GmbH do?
UCB Pharma GmbH is a pharmaceutical company based in Mettmann that develops, manufactures or distributes pharmaceutical products. The company is active in the German healthcare market.
Where is UCB Pharma GmbH located?
UCB Pharma GmbH is headquartered in Mettmann, Germany. More information can be found on the company's website.
What products does UCB Pharma GmbH distribute?
UCB Pharma GmbH is active in the pharmaceutical sector. Detailed information on the products offered and therapeutic areas can be found on the company's website or via the contact details provided.
More Pharmaceutical Companies in Mettmann
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.